NCT03586570 is a Phase 1 clinical trial of Aprocitentan 25mg in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd..

Who is sponsoring NCT03586570?

NCT03586570 is sponsored by Idorsia Pharmaceuticals Ltd..

What drugs are being tested in NCT03586570?

Interventions in NCT03586570: Aprocitentan 25mg, Placebo.

What condition does NCT03586570 study?

NCT03586570 studies Healthy Subjects.

Is NCT03586570 still recruiting?

NCT03586570 is currently completed. Last updated 23 November 2022.

Last reviewed 2022-11-23 · How we verify

NCT03586570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

Completed Phase 1 Last updated 23 November 2022

What this trial tests

Phase 1 trial testing Aprocitentan 25mg in Healthy Subjects in 20 participants. Completed in 10 September 2018.

Timeline

17 July 2018

Primary endpoint
10 September 2018

10 September 2018

Quick facts

Lead sponsor	Idorsia Pharmaceuticals Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	20
Start date	17 July 2018
Primary completion	10 September 2018
Estimated completion	10 September 2018
Sites	1 location across United States

Drugs / interventions tested

Aprocitentan 25mg — full drug profile →
Placebo

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Idorsia Pharmaceuticals Ltd. — full company profile →

Who can join

Adults 20 to 45, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Knowledge About Aprocitentan in Hypertension.
Bank-Mikkelsen EM, Grimm D, Wehland M. · · 2025 · PMID 41373585 · DOI 10.3390/ijms262311431

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Idorsia Pharmaceuticals Ltd. trials

Trials by the same sponsor.

NCT06799884 — A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormo · Phase 1 · completed
NCT05877222 — A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in · Phase 1 · completed
NCT05597020 — A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia · Phase 4 · completed
NCT05632393 — A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women · Phase 1 · completed
NCT05702177 — A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03586570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Idorsia Pharmaceuticals Ltd.
Last refreshed: 23 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03586570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing